SCHEMBL3202857

SCHEMBL3202857

CN(C)Cc1cnc(C(O)(c2ccccc2)C2CCC2)o1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 2/20 0.38
CHRM3 P20309 11/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
CYP2D6 P10635 1/20 0.38
HRH1 P35367 1/20 0.38
SCN1A P35498 1/20 0.38
KMT2A Q03164 1/20 0.38
SCN2A Q99250 1/20 0.38
SCN3A Q9NY46 1/20 0.38
POLB P06746 1/20 0.37
CHRM2 P08172 10/20 0.36
CHRM4 P08173 10/20 0.36
CHRM5 P08912 10/20 0.36
CHRM1 P11229 10/20 0.36
NPY2R P49146 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1109822 0.98 ALDH1A1 (0.40) ATML3MBTL1ALDH1A1CHRM3MEN1
SCHEMBL13329443 0.98 ALDH1A1 (0.40) ATML3MBTL1ALDH1A1CHRM3MEN1
SCHEMBL3218882 0.98 ALDH1A1 (0.40) ATML3MBTL1ALDH1A1CHRM3MEN1
SCHEMBL1109782 0.96 CHRM3 (0.41) ATML3MBTL1ALDH1A1CHRM3CYP2D6
SCHEMBL1109790 0.96 CHRM3 (0.41) ATML3MBTL1ALDH1A1CHRM3CYP2D6
SCHEMBL4739830 0.96 CHRM3 (0.41) ATML3MBTL1ALDH1A1CHRM3CYP2D6
SCHEMBL1109780 0.96 CHRM3 (0.41) ATML3MBTL1ALDH1A1CHRM3CYP2D6
SCHEMBL3225415 0.96 CHRM3 (0.41) ATML3MBTL1ALDH1A1CHRM3CYP2D6
SCHEMBL1109796 0.86 CHRM3 (0.39) ATML3MBTL1ALDH1A1CHRM3MEN1
SCHEMBL13329487 0.86 CHRM3 (0.39) ATML3MBTL1ALDH1A1CHRM3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056565-A1 Heterocyclic Derivatives as M3 Muscarinic Receptors ARGENTA DISCOVERY LIMITED (GB) 2010-03-04 US disclosed
CN-101657452-A Hete rocyclic derivatives as the M3 muscarinic receptor ARGENTA DISCOVERY LTD GB 2010-02-24 CN disclosed
EP-2121688-A1 HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS Argenta Discovery Ltd (GB) 2009-11-25 EP disclosed
WO-2008099186-A1 HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS ARGENTA DISCOVERY LIMITED (GB) 2008-08-21 WO disclosed
WO-2008096093-A1 OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES ARGENTA DISCOVERY LTD. (GB) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056565-A1 Heterocyclic Derivatives as M3 Muscarinic Receptors CHRM2, CHRM3, CHRM1 ATM 1350/4885L3MBTL1 1957/4885ALDH1A1 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.